These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33720879)

  • 1. Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies.
    Gupta HV; Beach TG; Mehta SH; Shill HA; Driver-Dunckley E; Sabbagh MN; Belden CM; Liebsack C; Dugger BN; Serrano GE; Sue LI; Siderowf A; Pontecorvo MJ; Mintun MA; Joshi AD; Adler CH
    J Alzheimers Dis; 2021; 80(4):1603-1612. PubMed ID: 33720879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.
    Siderowf A; Pontecorvo MJ; Shill HA; Mintun MA; Arora A; Joshi AD; Lu M; Adler CH; Galasko D; Liebsack C; Skovronsky DM; Sabbagh MN
    BMC Neurol; 2014 Apr; 14():79. PubMed ID: 24716655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging.
    Villemagne VL; Okamura N; Pejoska S; Drago J; Mulligan RS; Chételat G; O'Keefe G; Jones G; Kung HF; Pontecorvo M; Masters CL; Skovronsky DM; Rowe CC
    Neurodegener Dis; 2012; 10(1-4):161-5. PubMed ID: 22261520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies.
    Kantarci K; Lowe VJ; Boeve BF; Senjem ML; Tosakulwong N; Lesnick TG; Spychalla AJ; Gunter JL; Fields JA; Graff-Radford J; Ferman TJ; Jones DT; Murray ME; Knopman DS; Jack CR; Petersen RC
    Ann Neurol; 2017 Jan; 81(1):58-67. PubMed ID: 27863444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.
    Villemagne VL; Okamura N; Pejoska S; Drago J; Mulligan RS; Chételat G; Ackermann U; O'Keefe G; Jones G; Gong S; Tochon-Danguy H; Kung HF; Masters CL; Skovronsky DM; Rowe CC
    Arch Neurol; 2011 Jul; 68(7):905-12. PubMed ID: 21747030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinguishing between dementia with Lewy bodies and Alzheimer's disease using metabolic patterns.
    Ye BS; Lee S; Yoo H; Chung SJ; Lee YH; Choi Y; Lee PH; Sohn YH; Yun M
    Neurobiol Aging; 2020 Mar; 87():11-17. PubMed ID: 31791660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography.
    Koeppe RA; Gilman S; Junck L; Wernette K; Frey KA
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S67-76. PubMed ID: 18632004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy.
    Shimada H; Shinotoh H; Hirano S; Miyoshi M; Sato K; Tanaka N; Ota T; Fukushi K; Irie T; Ito H; Higuchi M; Kuwabara S; Suhara T
    Mov Disord; 2013 Feb; 28(2):169-75. PubMed ID: 23225334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy.
    Walker Z; Jaros E; Walker RW; Lee L; Costa DC; Livingston G; Ince PG; Perry R; McKeith I; Katona CL
    J Neurol Neurosurg Psychiatry; 2007 Nov; 78(11):1176-81. PubMed ID: 17353255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
    Cortes-Blanco A; Prieto-Yerro C; Martinez-Lazaro R; Zamora J; Jiménez-Huete A; Haberkamp M; Pohly J; Enzmann H; Zinserling J; Strassmann V; Broich K
    Alzheimers Dement; 2014 Oct; 10(5 Suppl):S395-9. PubMed ID: 24418060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies.
    McCleery J; Morgan S; Bradley KM; Noel-Storr AH; Ansorge O; Hyde C
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010633. PubMed ID: 25632881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion imaging in dementia with Lewy bodies: Associations with amyloid burden, atrophy, vascular factors and clinical features.
    Donaghy PC; Firbank M; Petrides G; Lloyd J; Barnett N; Olsen K; Thomas AJ; O'Brien JT
    Parkinsonism Relat Disord; 2020 Sep; 78():109-115. PubMed ID: 32814228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F] fluorodeoxyglucose in patients with dementia with Lewy bodies.
    Kasanuki K; Iseki E; Fujishiro H; Yamamoto R; Higashi S; Minegishi M; Togo T; Katsuse O; Uchikado H; Furukawa Y; Hino H; Kosaka K; Sato K; Arai H
    J Neurol Sci; 2012 Mar; 314(1-2):111-9. PubMed ID: 22041339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases.
    Lee SH; Cho H; Choi JY; Lee JH; Ryu YH; Lee MS; Lyoo CH
    Mov Disord; 2018 Feb; 33(2):262-272. PubMed ID: 29168583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies.
    Donaghy PC; Firbank MJ; Thomas AJ; Lloyd J; Petrides G; Barnett N; Olsen K; O'Brien JT
    Mov Disord; 2018 Jul; 33(7):1130-1138. PubMed ID: 29672930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks.
    Schumacher J; Gunter JL; Przybelski SA; Jones DT; Graff-Radford J; Savica R; Schwarz CG; Senjem ML; Jack CR; Lowe VJ; Knopman DS; Fields JA; Kremers WK; Petersen RC; Graff-Radford NR; Ferman TJ; Boeve BF; Thomas AJ; Taylor JP; Kantarci K
    Brain; 2021 Nov; 144(10):3212-3225. PubMed ID: 34114602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET Radioligands Reveal the Basis of Dementia in Parkinson's Disease and Dementia with Lewy Bodies.
    Gomperts SN; Marquie M; Locascio JJ; Bayer S; Johnson KA; Growdon JH
    Neurodegener Dis; 2016; 16(1-2):118-24. PubMed ID: 26655867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodality imaging characteristics of dementia with Lewy bodies.
    Kantarci K; Lowe VJ; Boeve BF; Weigand SD; Senjem ML; Przybelski SA; Dickson DW; Parisi JE; Knopman DS; Smith GE; Ferman TJ; Petersen RC; Jack CR
    Neurobiol Aging; 2012 Sep; 33(9):2091-105. PubMed ID: 22018896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.
    McKeith I; O'Brien J; Walker Z; Tatsch K; Booij J; Darcourt J; Padovani A; Giubbini R; Bonuccelli U; Volterrani D; Holmes C; Kemp P; Tabet N; Meyer I; Reininger C;
    Lancet Neurol; 2007 Apr; 6(4):305-13. PubMed ID: 17362834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a New Imaging Technique Using the Glucose Metabolism to Amyloid Deposition Ratio in the Diagnosis of Alzheimer's Disease.
    Takahashi R; Ishii K; Yokoyama K; For The Alzheimer S Disease Neuroimaging Initiative EY
    Curr Alzheimer Res; 2017; 14(2):161-168. PubMed ID: 27334941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.